Prevention through early detection of cancer

Novigenix has an established track record in early detection of cancer:

  • We have a special focus on oncology with proven products in the market
  • We deliver unique and novel intelligent insights
  • Our solution is simple to use in clinical trials and routine medical practice
  • We have a standardized workflow analysis for signal to noise optimization and precise detection of signals
  • We have a workflow driven practical approach that can be rolled out globally across clinical trial sites minimizing logistical complexity and cost while maximizing robustness and precision

Application Case Study: Early detection of colorectal cancer through COLOX™

The Novigenix-developed blood test COLOX™ is designed for detection of pre-cancerous legions (advanced adenomas) and early stage colorectal cancer. It offers a convenient solution for patients to be tested with no bowel preparation requirements. It is currently available on the Swiss market and can be ordered by the physician as part of a routine medical check-up.

COLOX™ is a new generation award-winning* RNA-based biomarker test that measures the immune system reaction to the onset of colorectal cancer (CRC). The test analyses the transcriptome of the peripheral blood mononuclear cells (PBMC´s) from a blood sample drawn in routine medical practice. Developed by Novigenix, COLOX™ is validated through a multi-centre clinical study, received regulatory approval in 2014, and has been used in medical practice in Switzerland since 2015 through our distribution partner UNILABS.

The COLOX™ blood test can be used by the family doctor as part of a routine medical screening for CRC, avoiding the inconvenience of bowel or stool preparation. The blood test is sent to a medical laboratory which provides the supporting service and carries out the COLOX™ test analysis. The test accurately and reliably detects colorectal cancer (78%) and adenomatous polyps (52%). This means that those that tested positive can be referred for colonoscopy to ascertain the presence of cancer or pre-cancerous lesions.

COLOX™ is intended for men and women who are not yet presenting symptoms of disease aged 45 and over. Patients who tested negative with COLOX® can continue to be monitored regularly without inconvenience as part of their regular health screening.

To learn more about COLOX™ please visit www.colox.ch

*COLOX™ received the Felix Burda Award for Medicine and Science category in 2021